Hopkins P N, Hunt S C, Schreiner P J, Eckfeldt J H, Borecki I B, Ellison C R, Williams R R, Siegmund K D
Cardiovascular Genetics, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City 84132, USA.
Atherosclerosis. 1998 Dec;141(2):333-45. doi: 10.1016/s0021-9150(98)00174-9.
A positive interaction between high plasma lipoprotein(a) [Lp(a)] and unfavorable plasma lipid levels has been reported to result in very high risk for premature coronary artery disease (CAD). We further examined this issue for men and women with early onset CAD. We also examined potential interactions between Lp(a) and non-lipid risk factors.
In 338 men and women with early onset CAD (most with a positive family history of early CAD) and 480 general population controls, we measured Lp(a), lipids and other risk factors. In univariate analysis, relative odds for CAD was 1.7 (P = 0.002) for plasma Lp(a) >50 mg/dl. Elevated Lp(a) level was found to interact with adjusted plasma total/high density lipoprotein (HDL) cholesterol such that when Lp(a) was over 50 mg/dl and adjusted plasma total/HDL cholesterol >5.8, relative odds for CAD were 8.0-9.6 (P<0.0001) in multiple logistic regression. Non-lipid risk factors were generally found to multiply the risk associated with Lp(a) (as predicted by logistic regression) without evidence for interaction.
We find evidence that Lp(a) does interact positively with adjusted plasma total/HDL cholesterol ratio. Aggressive risk factor intervention, especially for lipids, in those with elevated Lp(a) therefore appears indicated.
据报道,血浆脂蛋白(a)[Lp(a)]水平升高与不良血脂水平之间存在正向相互作用,会导致早发冠状动脉疾病(CAD)的风险极高。我们进一步研究了早发CAD男性和女性的这一问题。我们还研究了Lp(a)与非脂质风险因素之间的潜在相互作用。
在338例早发CAD患者(大多数有早发CAD的家族史阳性)和480例普通人群对照中,我们测量了Lp(a)、血脂及其他风险因素。在单因素分析中,血浆Lp(a)>50mg/dl时,CAD的相对比值为1.7(P = 0.002)。发现Lp(a)水平升高与校正后的血浆总胆固醇/高密度脂蛋白(HDL)胆固醇相互作用,使得当Lp(a)超过50mg/dl且校正后的血浆总胆固醇/HDL胆固醇>5.8时,多因素logistic回归中CAD的相对比值为8.0 - 9.6(P<0.0001)。一般发现非脂质风险因素会增加与Lp(a)相关的风险(如logistic回归所预测),但无相互作用的证据。
我们发现有证据表明Lp(a)确实与校正后的血浆总胆固醇/HDL胆固醇比值存在正向相互作用。因此,对于Lp(a)升高的患者,积极的风险因素干预,尤其是针对血脂的干预,似乎是必要的。